The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC) who purchased shares between November 25, 2019 and October 11, 2021. The action, which was filed in the United States District Court for the Northern District of California, alleges that the Company violated federal securities laws.
In particular, the Revance lawsuit alleges that (i) quality control deficiencies existed at the Company’s manufacturing facility for DaxibotulinumtoxinA for Injection (“DAXI”); (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration (“FDA”) would approve the DAXI Biologics License Application (“BLA”) in its current form; (iii) accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Shareholders have until February 8, 2022 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
To learn more and keep informed, complete this form >